Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells in
the bone marrow (BM). Despite the significant advances in treatment, MM is still a fatal …

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell
population with the ability to suppress innate and adaptive immune responses that promote …

Virtually all patients with multiple myeloma become unresponsive to treatment over time.
Relapsed/refractory multiple myeloma (RRMM) is accompanied by the clonal evolution of …

Precursor states of multiple myeloma (MM) and its native tumor microenvironment need in-
depth molecular characterization to better stratify and treat patients at risk. Using single-cell …

Despite advancements in understanding the pathophysiology of Multiple Myeloma (MM), the
cause of rapid progressing disease in a subset of patients is still unclear. MM's progression …

Multiple myeloma is the most common indication for high-dose chemotherapy and
autologous stem cell transplantation (ASCT), and lenalidomide maintenance after transplant …

Early alterations within the bone marrow microenvironment that contribute to the progression
of multiple myeloma (MM) from its precursor stages could be the key to identifying novel …

Despite major treatment advances in recent years, patients with multiple myeloma inevitably
relapse. The RNA polymerase II complex has been identified as a promising therapeutic …

The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more
frequently investigated in transplant-eligible patients than in elderly patients. Because an …

As vast strides are being made in the management and treatment of multiple myeloma (MM),
recent interests are increasingly focusing on understanding the development of the disease …